相关实验视频

Updated: Jan 14, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

肝细胞癌中的CHMP4A:探索其在瘤进展,免疫调节中的作用,以及与TIM3检查点的潜在联系

Kai Sun¹, Song Wen¹, Shou-Jun Guo¹

¹Department of Oncology, Ganzhou Cancer Hospital, The Affiliated Cancer Hospital of Gannan Medical University, Ganzhou, Jiangxi, China.

Frontiers in immunology

|October 20, 2025

概括

充电多细胞体蛋白4A (CHMP4A) 在肝癌中过度表达,促进瘤生长和免疫逃避. 向CHMP4A可能为肝肝细胞癌 (LIHC) 提供一种新的治疗策略.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
免疫学免疫学免疫学

背景情况:

充电多晶体体蛋白4A (CHMP4A) 是一种ESCRT-III蛋白质,参与了膜动力学.
新出现的证据表明CHMP4A在癌症免疫治疗中的作用.
肝肝细胞癌 (LIHC) 由于复杂的病变发生和治疗耐药性而带来挑战.

研究的目的:

研究CHMP4A在LIHC进展中的作用.
评估CHMP4A作为LIHC中的预后生物标志物和治疗标.

主要方法:

使用TCGA,GEO,ArrayExpress和ICGC数据集进行泛癌分析.
生物信息学分析,免疫组织化学和卡普兰-梅尔生存分析.
单细胞转录组学,siRNA介导的淘汰和免疫景观分析.

主要成果:

在LIHC组织中,CHMP4A显著过度表达,与患者的不良结果相关.
CHMP4A knockdown 抑制了LIHC细胞的增殖,迁移和入侵,调节了上皮细胞-介质细胞过渡 (EMT).
CHMP4A表达与免疫细胞透,检查点分子,TMB,MSI和TIM3/LGALS9免疫检查点轴相关.

结论:

通过致癌和免疫调节机制,CHMP4A是LIHC进展的关键驱动因素.
CHMP4A促进瘤生长和转移潜力.
CHMP4A影响瘤免疫微环境,特别是TIM3/LGALS9通路,表明其作为LIHC治疗标和预后生物标记物的潜力.

关键词:

在CHMP4A中.时间3 TIM3 肝细胞癌是肝细胞癌.免疫透免疫透是什么?预后预后预后

更多相关视频

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Published on: April 25, 2025

相关概念视频

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...